

## Abstract

### **Recent advances in the systemic treatment of AD – new era of targeted biologics**

Stephan Weidinger, Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany

Atopic dermatitis (AD) is one of the most common chronic inflammatory skin disease globally. For decades, the treatment landscape of AD has remained stagnant with little innovation, with topical corticosteroids as the mainstay of treatment, and short-term use of rather unspecific systemic immunosuppressants in patients whose disease is inadequately controlled by topicals. With the two biologics dupilumab and tralokinumab as well as the small-molecule Janus kinase inhibitors baricitinib, upadacitinib and abrocitinib there are now advanced treatment options available that provide better management options. Dupilumab is the first-in-class representative of targeted treatments specifically addressing type-2 pathways, and multiple trials have demonstrated its robust efficacy and favorable safety across age groups and ethnicities. There is now also increasing evidence from real-world studies on its effectiveness and safety, and from exploratory studies on its effects on the molecular level. This presentation will provide an overview on current systemic treatment options for moderate to severe AD with a focus on biologics